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What is already known on this topic?
 ► Endotracheal intubation is stressful and painful 
and causes multiple adverse effects.
 ► Non- emergency endotracheal intubation in 
neonates should always be performed with the 
use of premedication.
 ► Despite its off- label use, the lack of clear dosing 
guidelines and concerns about safety, propofol 
is widely used in this context.
What this study adds?
 ► Effects and side effects of propofol are highly 
variable and unpredictable with extensive 
interindividual variability.
 ► Relatively high doses are needed to provide 
effective sedation and propofol carries a high 
risk of hypotension, even when initial low doses 
are used.
 ► Propofol in the neonatal population should be 
used with careful consideration.
AbsTrACT
Objective To find propofol doses providing effective 
sedation without side effects in neonates of different 
gestational ages (GA) and postnatal ages (PNA).
Design and setting Prospective multicentere dose- 
finding study in 3 neonatal intensive care units.
Patients Neonates with a PNA <28 days requiring non- 
emergency endotracheal intubation.
Interventions Neonates were stratified into 8 groups 
based on GA and PNA. The first 5 neonates in every group 
received a dose of 1.0 mg/kg propofol. Based on sedative 
effect and side effects, the dose was increased or decreased 
in the next 5 patients until the optimal dose was found.
Main outcome measures The primary outcome was 
the optimal single propofol starting dose that provides 
effective sedation without side effects in each age group.
results After inclusion of 91 patients, the study was 
prematurely terminated because the primary outcome 
was only reached in 13% of patients. Dose- finding was 
completed in 2 groups, but no optimal propofol dose 
was found. Effective sedation without side effects was 
achieved more often after a starting dose of 2.0 mg/
kg (28%) than after 1.0 mg/kg (3%) and 1.5 mg/kg 
(9%). Propofol- induced hypotension occurred in 59% 
of patients. Logistic regression analyses showed that 
GA and PNA did not predict effective sedation or the 
occurrence of hypotension.
Conclusions Effective sedation without side effects is 
difficult to achieve with propofol and the optimal dose in 
different age groups of neonates could not be determined. 
The sedative effect of propofol and the occurrence of 
hypotension are unpredictable and show large inter- 
individual variability in the neonatal population.
InTrODuCTIOn
As awake intubation has multiple harmful effects,1–7 
the routine use of premedication before non- 
emergency intubation in neonates has become 
standard of care.8–11 However, there is insufficient 
knowledge and lack of consensus about the most 
effective and safe strategy. Propofol is considered 
one of the acceptable options, despite being off- label 
for use in newborns, gaps in knowledge regarding 
optimal dosing and concerns about safety.12 Because 
of its rapid onset and recovery, and its ease of use, 
propofol as a sedative for endotracheal intuba-
tion has been implemented into clinical practice in 
several neonatal intensive care units (NICUs).13–17 
Previous trials studying propofol have shown 
conflicting results on sedative effect and concerning 
effects on blood pressure.16–19
Used propofol starting doses range from 1.0 to 
2.5 mg/kg, with cumulative doses ranging from 1.0 
to 6.0 mg/kg for successful intubation.15–19 Although 
gestational age (GA) and postnatal age (PNA) are 
important determinants of propofol pharmaco-
kinetics,20 fixed propofol starting doses are often 
used for the entire neonatal population regardless 
of GA and PNA. The Exploratory Propofol Dose- 
Finding Study In Neonates (NEOPROP) is the 
only available dose- finding study in newborns that 
recently determined the effective propofol dose 
in 50% (EC50) of patients for three different GA 
groups. This study also showed a great decrease in 
mean arterial blood pressure and 62% incidence of 
hypotension.21
It is crucial to find propofol doses that are safe 
and effective in the entire newborn population. 
Therefore, we performed the NEOPROP-2 trial, 
which aimed to find age- specific propofol starting 
doses that provide effective sedation without side 
effects in neonates.
MeThODs
study design and setting
A prospective multicentre dose- finding study was 
conducted at three level III NICUs in the Neth-
erlands between July 2014 and January 2018. An 
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Figure 1 Group allocation.
interim analysis was planned after every 6 months of inclusion, 
by an independent data and safety monitoring committee. The 
parents of all included patients provided written informed 
consent.
Participants
Neonates were eligible if they had a PNA of <28 days and 
required non- emergency endotracheal intubation. Exclusion 
criteria were major congenital anomalies or neurological disor-
ders, upper airway anomalies, sedative or opioid administration 
in the preceding 24 hours and previous inclusion in the trial. The 
use of propofol was left to the discretion of the attending physi-
cian. If the haemodynamic status was judged to be sufficiently 
stable to use propofol, the patient could be included. Patients 
were stratified into eight different groups by GA and PNA 
(figure 1), based on expected variation in effect and propofol 
clearance.
Interventions
Intubation procedure
Propofol was used as standard of care for endotracheal intuba-
tion in our units. Propofol (Fresenius Kabi, Schelle, Belgium) 
was administered as intravenous bolus followed by a saline flush 
for a total duration of 30 s. After propofol administration, the 
pre- intubation sedation level was assessed every 30 s up to 3 min 
after the infusion, using the Intubation Readiness Score (IRS).22 
When the pre- intubation sedation level was adequate, intubation 
was continued. In the case of insufficient pre- intubation seda-
tion level after 3 min, additional propofol was administered until 
the pre- intubation sedation level was sufficient. The amount of 
each additional propofol dose was left at the discretion of the 
attending physician. After intubation, the quality of intubation 
was measured by the Viby- Mogensen intubation score.23 Data 
regarding propofol doses and intubation attempts were reported.
Dose-finding approach
A sample size of five patients per dose per group was used, based 
on the large interindividual variability in effects of propofol that 
was found previously.17 The first five patients in every group 
received a starting dose of 1.0 mg/kg propofol. Based on these 
five patients, the dose was increased or decreased with 0.5 mg/
kg in the next five patients up to a maximum starting dose of 
3.5 mg/kg because of expected toxicity. If needed for further 
optimisation, a change of 0.25 mg/kg was applicable in the final 
dose- finding stage. Once the optimal propofol dose had been 
found, it was confirmed in another five patients. Dose finding 
was completed per group when the optimal propofol dose was 
found, or when the maximum starting dose of 3.5 mg/kg was 
reached.
Primary outcome measures
The primary outcome of the study was the optimal single 
propofol starting dose for intubation in neonates with different 
GAs and PNAs defined as the single starting dose that provided 
effective sedation without significant side effects. Effective seda-
tion was determined with two variables that both needed to 
be adequate: pre- intubation sedation level and quality of intu-
bation. Pre- intubation sedation level was determined with the 
IRS, and adequate pre- intubation sedation level was defined as 
IRS 3 or 4.22 Quality of intubation was measured by the Viby- 
Mogensen intubation score.23 Good quality of intubation was 
defined as a score of ≤2 on each of the five items.
Predefined side effects included hypotension, myoclonus, 
chest wall rigidity, persistent respiratory and/or circulatory 
failure and bronchospasm. Blood pressure was measured inva-
sively if an indwelling arterial catheter was present. Data were 
collected every minute from 5 min before until 30 min after the 
start of propofol administration, every 5 min from 30 to 60 min 
and every hour thereafter up to 24 hours. When no arterial cath-
eter was present, blood pressure was measured non- invasively by 
an appropriately sized cuff every 5 min from 5 min before until 
60 min after propofol administration and every hour thereafter 
until 24 hours. Propofol- induced hypotension was defined as a 
mean blood pressure (MBP) below postmenstrual age (PMA) 
detected in the first hour after propofol administration. Treat-
ment of hypotension was left to the discretion of the treating 
physician.
For the primary outcome both effective sedation and absence 
of serious side effects needed to be positive. When either seda-
tion was not effective or tthere were serious side effects, the 
primary outcome was not reached. Since both items needed to 
be positive, in case of one negative item and one missing item, 
the primary outcome was also not reached.
secondary outcome measures
Secondary outcomes were the optimal propofol starting dose in 
the entire study population (regardless of age group), the need 
for additional doses of propofol and side effects in the entire 
study population and sedative effect and side effects in the most 
frequently used propofol starting doses. Finally, a logistic regres-
sion analysis was performed to find potential variables predicting 
the sedative effect and side effects after propofol.
statistical analysis
The predefined sample size depended on which propofol 
dose was found to be adequate in five consecutive patients 
per group. Data were analysed using SPSS (IBM SPSS Statis-
tics for Windows, V.22.0. Armonk, New York, USA), and R 
V.3.5 (R Core Team, Vienna, Austria). Patients were analysed 
according to the intention- to- treat principle. Baseline character-
istics were described by percentages for qualitative variables and 
median (IQR) for quantitative variables. Comparison between 
dosing groups was performed with the Mann- Whitney U test 
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Figure 2 Dose finding in groups 3 and 5. *Missing data on blood 
pressure, in the dose- finding approach considered to be normal in the 
absence of evidence of hypotension; #missing data on intubation score, 
effective sedation only judged by pre- intubation sedation level. In group 
5, the 1.0 and 1.5 mg/kg dosing subgroups both contain six instead of 
five patients. This was due to initial uncertainty of the suitability of the 
data for the primary outcome in one patient in both subgroups. An extra 
patient in both groups was included to ensure of total of five patients 
with viable data on the primary outcome. After re- evaluation the data of 
all six patients in both subgroups turned out to be suitable.
for continuous variables and the Pearson’s χ2 test or the Fish-
er’s exact test, as appropriate, for categorical variables. Logistic 
regression analysis was performed to identify factors influencing 
the sedative effect and side effects of propofol with primary 
outcome, effective sedation and hypotension as outcome vari-
ables. We analysed the effects of gestational age (weeks), birth 
weight <10th percentile, male gender, postnatal age (hours) and 
propofol starting dose (mg/kg) on primary outcome and effec-
tive sedation. Total amount of propofol (mg/kg) was added as a 
confounder in the logistic regression analysis with hypotension 
as outcome variable. We used the Firth’s method to reduce the 
bias in logistic regression that arises as a consequence of the rela-
tively small sample size.24 25
resulTs
study population
The study population consisted of 91 patients (see table 1). 
Three patients were included despite their PNA exceeding 28 
days (two patients in group 2 (39 and 32 days) and one patient 
in group 4 (29 days)).
study termination
An interim analysis after inclusion of 91 patients demonstrated 
a low inclusion rate in several groups and a 59% incidence of 
hypotension. In two age groups a propofol dose that provided 
effective sedation was found but caused hypotension in the 
majority of patients. Therefore, an optimal dose as predefined 
in the primary outcome in these two groups was not established. 
The study was prematurely terminated, therefore, in consulta-
tion with the data safety monitoring committee.
Primary outcome
Dose finding was only completed in groups 3 and 5, without 
finding an optimal propofol dose. The results of the dose- finding 
approach in sequential patients in groups 3 and 5 are presented 
in figure 2. In both groups, starting doses of 1.0 and 1.5 mg/kg 
almost never led to effective sedation. A starting dose of 2.0 mg/
kg led to effective sedation in many patients, but also led to a 
high incidence of hypotension, even after confirming this dose 
in another five patients per group. The dose, therefore, was 
decreased to 1.75 mg/kg, which did not provide effective seda-
tion in the majority of patients in both groups.
secondary outcomes
In the entire study population, effective sedation without side 
effects was achieved in only 12 patients (13%). Additional 
propofol was administered in 65 patients (71%) and the median 
cumulative propofol dose for successful intubation was 3.0 mg/
kg (range 1.0–6.0 mg/kg, IQR 2.0–3.75).
Propofol starting doses of 1.0, 1.5 and 2.0 mg/kg were used in 
further in- depth analyses. There were no differences in patient 
characteristics between the three groups, with the exception of 
PNA (table 2). This was lower in the 2.0 mg/kg dosing group, 
due to the higher inclusion numbers at younger postnatal ages. 
A starting dose of 2.0 mg/kg much more often led to effective 
sedation than starting doses of 1.0 and 1.5 mg/kg. The incidence 
of hypotension, however, was not different between the three 
starting doses.
Sufficient MBP data after propofol administration were 
available for 82 patients (90%). Propofol- induced hypotension 
occurred in 48 (59%) patients. Of these, 26 patients (54%) 
were treated with volume resuscitation. Therapy with inotropes 
was started in nine patients (10%) at a median of 298 min after 
propofol administration (IQR 125–917 min). In seven of these 
patients, inotropes were started >2 hours after the start of 
propofol administration. In two other patients, inotropes were 
started within 2 hours and the hypotension is probably attrib-
utable to propofol. Comparison of MBP data before and after 
propofol was possible in 80 patients (88%). MBP decreased with 
a median of 34% (95% CI 36.5% to 29.1%) compared with 
baseline MBP. The lowest MBP was measured at a median of 
21 min (95% CI 19.3 to 26.2 min).
Other side effects occurred in 10 patients (11%), including 
myoclonus in 8 patients (9%), bronchospasm in 1 patient (1%) 
and vocal cord spasm in 1 patient (1%). A total of 15 patients 
(16%) died at a median of 12 days after inclusion in this trial 
(range 0–57 days). Twelve patients died >72 hours after inclu-
sion in the trial. One patient died from sepsis within 24 hours, 
and two patients died from necrotising enterocolitis between 24 
and 48 hours after inclusion. None was judged as directly attrib-
utable to the propofol administration.
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Table 2 Patient characteristics and outcomes in three starting doses
Dosing groups Comparison between groups
1.0 mg/kg
(n=30)
1.5 mg/kg
(n=23)
2.0 mg/kg
(n=26) 1.0 vs 1.5 1.0 vs 2.0 1.5 vs 2.0
Patient characteristics
Gestational age (week), median (IQR) 27.5 (25.86–30.93) 26.86 (25.57–30.14) 29.07 (26.43–31.71) P=0.37 P=0.66 P=0.20
Birth weight (g), median (IQR) 1075 (784–1410) 908 (780–1600) 1215 (895–1568) P=0.46 P=0.51 P=0.19
Postnatal age (hour), median (IQR) 156 (12–397) 37.35 (21–387) 19.58 (8–43) P=0.68 P=0.01 P=0.04
Male gender, n (%) 22 (73) 12 (52) 18 (69) P=0.16 P=0.77 P=0.25
Propofol dosing
Extra propofol administered, n (%) 25 (83) 20 (87) 11 (42) P=1.0 P=0.002 P=0.002
Cumulative propofol dose (mg/kg), median (IQR) 3.0 (1.9–4.0) 3.4 (2.5–4.5) 2.0 (2.0–3.0) P=0.06 P=0.97 P=0.03
Primary outcome
No. of patients with data available 30 (100)* 23 (100)† 25 (96)‡    
Effective sedation without side effects, n (%) 1 (3) 2 (9) 7 (28) P=0.57 P=0.02 P=0.15
Sedative effect of propofol
Adequate pre- intubation sedation level, n (%) 7 (23) 7 (30) 24 (92) P=0.75 P<0.001 P<0.001
Quality of intubation     
  No. of patients with data available 3 (10) 7 (30) 19 (73)    
  Good quality of intubation 1 (33) 3 (43) 18 (95) P=0.18 P=0.02 P=0.003
Effective sedation     
  No. of patients with data available 28 (93) 23 (100) 21 (81)    
  Effective sedation, n (%) 1 (4) 3 (13) 18 (86) P=0.21 P<0.001 P<0.001
  Hypotension
No. of patients with data available 24 (80) 21 (91) 26 (100)    
Occurrence of hypotension, n (%) 15 (63) 11 (52) 16 (62) P=0.55 P=1.0 P=0.57
Volume resuscitation, n (% of hypotensive patients) 7 (47) 4 (36) 12 (75) P=0.86 P=0.18 P=0.09
*Both patients with missing data on effective sedation had side effects and all six patients with missing data on side effects had insufficient sedation. Therefore, a conclusion on 
the primary outcome could be drawn for all 30 patients.
†Both patients with missing data on side effects had inadequate sedation and, therefore, a conclusion on the primary outcome could be drawn on all 23 patients.
‡In four patients with missing data on effective sedation, side effects were present and in only one patient both data on effective sedation and side effects were missing. 
Therefore, a conclusion on the primary outcome could be drawn in 25 out of 26 patients.
Table 3 Logistic regression analysis with different outcome variables: primary outcome, effective sedation and hypotension
Primary outcome
(n=89)
effective sedation
(n=83)
hypotension
(n=82)
Or 95% CI P value Or 95% CI P value Or 95% CI P value
Gestational age (weeks) 0.94 0.77 to 1.15 0.54 1.00 0.80 to 1.23 0.98 1.09 0.94 to 1.26 0.26
Birth weight <10th percentile (yes/no) 0.85 0.22 to 3.34 0.82 1.07 0.27 to 4.27 0.93 1.55 0.52 to 4.25 0.47
Male gender (yes/no) 1.72 0.46 to 6.40 0.42 2.67 0.76 to 9.36 0.13 0.94 0.36 to 2.45 0.90
Postnatal age (in hours) 1.00 0.99 to 1.00 0.69 1.00 0.99 to 1.00 0.65 1.00 0.99 to 1.00 0.45
Starting dose of propofol (mg/kg) 4.50 0.92 to 22.11 0.06 57.04 7.58 to 429.49 <0.001 1.09 0.35 to 3.39 0.88
Cumulative dose of propofol (mg/kg) 0.74 0.48 to 1.14 0.18
Corrected by Firth’s method to reduce bias because of relatively small sample size.
The results of the logistic regression analysis (table 3) showed 
that GA and PNA did not influence the effectiveness or safety 
of propofol.
DIsCussIOn
This dose- finding trial was designed to find the optimal single 
propofol dose for non- emergency endotracheal intubation 
providing effective sedation without significant side effects in 
neonates of different GAs and PNAs. To the best of our knowl-
edge, this is the largest drug dose- finding study performed in the 
neonatal population. Unfortunately, dose finding could only be 
completed in two of the eight defined age groups without deter-
mination of the optimal propofol dose. Our results show a dose- 
dependent relationship for propofol to reach effective sedation. 
However, we also found the sedative effect to be unpredictable 
in the individual patient, and propofol is associated with a high 
incidence of hypotension. Based on these results, propofol might 
probably be not the most suitable premedication prior to endo-
tracheal intubation in all neonates.
In contrast to our results, Smits et al were able to calculate 
specific propofol doses for preterm newborns in the first days 
of life that increased with GA.21 Their suggested propofol doses 
were lower than the doses that resulted in adequate sedation in 
our study. This difference could be explained by different ways 
of analyses and outcome parameters in both studies. We did not 
calculate the EC50, but showed that 2.0 mg/kg propofol starting 
dose is effective in 86% of patients.
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The available literature shows conflicting results on the seda-
tive effect of propofol. Doses of 1.0 and 2.5 mg/kg are found 
to provide sufficient sedation in some studies,16 18 while other 
studies found insufficient sedation with doses of 1.0, 2.0 and 
2.5 mg/kg.17 19 These conflicting data underline that the sedative 
effect of propofol is difficult to predict. The indication for intu-
bation could also play a role. For the Intubation–SURfactant–
Extubation (INSURE) procedure, duration of sedation should 
be very short.26 Therefore, clinicians might accept lower levels 
of sedation to diminish the risk of insufficient respiratory drive 
after the administration of surfactant and, therefore, the inability 
to immediately extubate the patient. However, regardless of 
the procedures that follow intubation, the act of laryngoscopy 
is equally stressful and equal levels of sedation should in our 
opinion be pursued.
GA and PNA are known covariates in propofol pharmaco-
kinetics.20 Therefore, we hypothesised that infants of different 
GAs and PNAs would need different propofol doses. Logistic 
regression analysis did not show a statistically significant effect 
of GA and PNA on the outcomes effective sedation and hypo-
tension. Although unclear, the extended interindividual vari-
ability in the effect of propofol seems much more important 
than GA and PNA in predicting the effect. Titrating propofol 
until the desired effect is achieved in the individual patient is 
probably the only way to ensure effective sedation in every 
patient. This, however, might still lead to a high incidence of 
hypotension.
Propofol is known for its pronounced effect on blood pres-
sure in the neonatal population. We found a median decrease in 
MBP of 34%, which is in accordance with other studies.16 17 21 
The incidence of hypotension of 59% was comparable to that 
reported by Smits et al (64%),21 but much higher than founded 
by Welzing et al (38%).16 This could be explained by the much 
smaller study sample, the lower dosages and the different defi-
nition of hypotension.16 Ghanta et al did not report hypoten-
sion.18 This could be explained by the possibility that MBP 
measurements were not continued long enough to detect hypo-
tension, as hypotension appears at a median of 10–20 min after 
propofol.16 17 Because of the pronounced effect that propofol 
can have on blood pressure, the haemodynamic status of the 
patient should be carefully evaluated before propofol is admin-
istered. In case of (impeding) haemodynamic compromise, other 
premedication with less pronounced effects on blood pressure 
should be considered.
Although blood pressure decrease after propofol is marked 
and there is a high incidence of hypotension, the implications for 
the short- term and long- term outcome are unclear. Blood pres-
sure alone is a poor indicator of cardiovascular status.27 In 95% 
of patients in the dose- finding study by Smits et al, cerebral auto-
regulation was intact during episodes of hypotension.28 In the 
absence of clinical signs of shock, they labelled these episodes 
of hypotension as permissive.21 Two other small studies on the 
cerebral effects of propofol in the neonatal population also 
showed no important correlation between blood pressure and 
cerebral oxygenation.29 30 Although these findings are certainly 
reassuring, there is insufficient evidence on the short- term and 
long- term consequences of propofol- induced hypotension and 
blood pressure decrease to draw final conclusions. Until this is 
clarified in further studies, we should in our opinion be careful 
with designating propofol- induced hypotension and blood pres-
sure decrease as permissive. On the other hand, the negative 
effects of propofol must be set against the negative effects of 
other premedication strategies. Almost all opioids, hypnotics 
and muscle relaxants also carry a risk of hypotension, and 
with fentanyl and remifentanil, there is also a risk of chest wall 
rigidity.12
Our study has several limitations. First, we were unable to 
perform dose finding as planned because patient inclusion in 
several groups proved to be very difficult. Reasons were insuf-
ficient time for achieving parental consent, and the very low 
incidence of endotracheal intubation in the higher gestational 
age groups. Second, we used a very strict definition of hypoten-
sion. Even a single measurement of MBP below PMA in the first 
60 min after propofol was marked as hypotension. It is question-
able whether this single measurement of MBP below PMA has 
any clinical relevance. Adding a time element to the definition 
may better reflect the patients with clinically relevant hypoten-
sion. Unfortunately, we were unable to provide synchronised 
neuromonitoring data, which could have helped to study the 
clinical relevance of hypotension on cerebral oxygenation and 
perfusion in greater detail. Third, the treatment of hypoten-
sion was left to the discretion of the treating physician, which is 
likely to have caused variability between clinicians and between 
centres.
COnClusIOns
The results of this large dose- finding study suggest that in the 
neonatal population it is difficult to achieve effective sedation 
without the occurrence of significant side effects with a single 
propofol bolus. The effects and side effects of propofol in the 
neonatal population are highly variable and unpredictable. 
Propofol in the neonatal population should only be used after 
careful consideration in each individual patient and should be 
titrated based on the sedative effect with strict monitoring of 
blood pressure and haemodynamic status. As long as the ideal 
premedication strategy in the neonatal population has not been 
elucidated, the pros and cons of different strategies including 
propofol should be balanced against each other. A greater effort 
should be made to move forward from a one- strategy- fits- all idea 
towards personalised neonatal pharmacology.
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